SANA BIOTECHNOLOGY INC
NASDAQ: SANA (Sana Biotechnology, Inc.)
Kemas kini terakhir: 18 jam lalu2.89
0.00 (0.00%)
| Penutupan Terdahulu | 2.89 |
| Jumlah Dagangan | 3,495,169 |
| Harga / Buku (P/B) | 5.97 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.880 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.67% |
| Nisbah Semasa (MRQ) | 3.40 |
| Aliran Tunai Operasi (OCF TTM) | -206.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -118.45 M |
| Pulangan Atas Aset (ROA TTM) | -23.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -71.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sana Biotechnology, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.67 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.46% |
| % Dimiliki oleh Institusi | 89.37% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |